NICE rules that drug used in advanced liver cancer is not cost effective for the NHS.
作者信息
Mayor Susan
出版信息
BMJ. 2009 Nov 23;339:b4956. doi: 10.1136/bmj.b4956.
PMID:19933742
Abstract
摘要
相似文献
1
NICE rules that drug used in advanced liver cancer is not cost effective for the NHS.英国国家卫生与临床优化研究所（NICE）规定，用于晚期肝癌的药物对英国国民医疗服务体系（NHS）而言不具有成本效益。
BMJ. 2009 Nov 23;339:b4956. doi: 10.1136/bmj.b4956.
2
Baying for a flexible drug price.
Lancet. 2009 Nov 28;374(9704):1794. doi: 10.1016/S0140-6736(09)62045-6.
3
Health-related quality of life and sorafenib.健康相关生活质量与索拉非尼
Hepatology. 2010 Oct;52(4):1523. doi: 10.1002/hep.23756.
4
Sorafenib for the treatment of advanced hepatocellular carcinoma.索拉非尼治疗晚期肝细胞癌。
Health Technol Assess. 2010 May;14 Suppl 1:17-21. doi: 10.3310/hta14Suppl1/03.
5
From a cancer drug fund to value based pricing of drugs.从癌症药物基金到基于价值的药品定价。
BMJ. 2010 Aug 12;341:c4388. doi: 10.1136/bmj.c4388.
6
Economic evaluation of sorafenib in unresectable hepatocellular carcinoma.索拉非尼治疗不可切除肝细胞癌的经济学评价。
J Gastroenterol Hepatol. 2010 Nov;25(11):1739-46. doi: 10.1111/j.1440-1746.2010.06404.x.
7
Impact of restricting access to high-cost medications for hepatocellular carcinoma.限制肝癌高费用药物的可及性的影响。
Expert Rev Pharmacoecon Outcomes Res. 2012 Aug;12(4):465-73. doi: 10.1586/erp.12.33.
8
Watchdog set to reject four drugs for kidney cancer on the NHS.监督机构准备拒绝国民保健制度（NHS）为肾癌开出的四种药物。
BMJ. 2008 Aug 14;337:a1262. doi: 10.1136/bmj.a1262.
9
Liver cancer drug is rejected for routine NHS use but will remain in Cancer Drugs Fund.一种肝癌药物被拒绝用于英国国家医疗服务体系（NHS）的常规治疗，但将保留在癌症药物基金中。
BMJ. 2017 Jan 3;356:i6864. doi: 10.1136/bmj.i6864.
10
Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma.索拉非尼二线治疗晚期肾细胞癌的成本效果分析。
Value Health. 2010 Jan-Feb;13(1):55-60. doi: 10.1111/j.1524-4733.2009.00616.x. Epub 2009 Sep 25.
Zotero 插件